Table 1.
Patients' characteristics before the start of ARTA.
| Abiraterone Acetate (N=10) | Enzalutamide (N=21) | Total (N = 31) | P-value | ||
|---|---|---|---|---|---|
| Age, years | Median (Q1–Q3) | 69.5 (66.5;73.2) | 78 (73;82) | 75 (69.5;80.5) | 0.031‡ |
| PSA, ng/ml | Median (Q1–Q3) | 33.3 (8.2;65.7) | 19.2 (9.4;53.4) | 19.2 (8.4;58.6) | 0.767‡ |
| Time to CRCP, months | Median (Q1–Q3) | 36.5 (19.5;48.9) | 38.1 (19.2;56.4) | 38.1 (19.1;53.1) | 0.800‡ |
| N, 109/L | Median (Q1-Q3) | 4.1 (2.7;5.1) | 3.7 (2.7;5.0) | 3.7 (2.7;5.0) | 0.767‡ |
| Ly, 109/L | Median (Q1-Q3) | 1.6 (1.1;2.1) | 1.8 (1.4;2.4) | 1.7 (1.3;2.3) | 0.228‡ |
| N/L | Median (Q1–Q3) | 2.3 (1.4;4.3) | 1.7 (1.4;2.4) | 1.9 (1.4;3.0) | 0.375‡ |
| Hb, g/L | Median (Q1–Q3) | 134.5 (129.2;135.0) | 131.0 (122.0;135.0) | 132.0 (124.5;135.0) | 0.421‡ |
| Site of metastasis | Lymph node | 2 (20.0%) | 5 (23.8%) | 7 (22.6%) | 1.00° |
| Bone | 5 (50.0%) | 9 (42.8%) | 14 (45.2%) | ||
| Lymph node, bone | 3 (30.0%) | 6 (28.6%) | 9 (29.0%) | ||
| Visceral | 0 | 1 (4.8%) | 1 (3.2%) | ||
| ECOG PS | 0 | 6 (60.0%) | 4 (19.0%) | 10 (32.3%) | 0.040° |
| 1–2 | 4 (40.0%) | 17 (81.0%) | 21 (67.7%) | ||
| Gleason score | < =7 (5–7) | 3 (30.0%) | 4 (22.2%) | 7 (25.0%) | 0.674° |
| >7 (8–10) | 7 (70.0%) | 14 (77.8%) | 21 (75.0%) | ||
| Missing | 3 | 3 |
PSA, prostate-specific antigen; Time to CRPC, time to development of castration-resistance; N, neutrophils; Ly, lymphocytes; N/L, neutrophil-lymphocyte ratio; HB, hemoglobin; ECOG PS, Eastern Cooperative Oncology Group Performance Status. Data are expressed as median (interquartile range) for continuous data and n (percentage) for categorical data.
‡
Kruskal-Wallis test;
°
Fisher's Exact Test.